TMT1A and colon adenocarcinoma: METTL7A was remarkably decreased in bladder urothelial carcinoma (BLCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), BRCA, COAD, cholangio carcinoma (CHOL), esophageal carcinoma (ESCA), kidney chromophobe (KICH), head and neck squamous cell carcinoma (HNSC), KIRC, kidney renal papillary cell carcinoma (KIRP), LUAD, liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC), rectum adenocarcinoma (READ), PRAD, stomach adenocarcinoma (STAD), THCA, and UCEC, while was only increased in glioblastoma multiforme (GBM) (Fig. 1A).